Last reviewed · How we verify
NCT05807503
Evaluation of the Effect of Neuroprotective Drug on Treatment Result in Patients After Traumatic Brain Injury
trial testing Cerebrolysin in TBI (Traumatic Brain Injury) in 56 participants. Completed in 30 November 2022.
31 October 2022
Quick facts
| Lead sponsor | Pomeranian Medical University Szczecin |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 56 |
| Start date | 1 February 2020 |
| Primary completion | 31 October 2022 |
| Estimated completion | 30 November 2022 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- Cerebrolysin — full drug profile →
Conditions studied
- TBI (Traumatic Brain Injury) — all drugs for TBI (Traumatic Brain Injury) →
Sponsor
Pomeranian Medical University Szczecin
Who can join
18 and older, any sex, with TBI (Traumatic Brain Injury). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Traumatic Brain Injury TBI is one of the most common causes of death and recovery failure worldwide. Each element of treatment, starting from possible surgical treatment, patient monitoring and neuroprotective treatment, can be important in the overall outcome of patients' treatment. More and more elements of treatment are discussed in the literature in the multimodal approach to the patient with a trauma to the central nervous system. Cerebrolysin is a drug with a proven beneficial effect on the prognosis of patients with TBI. In our trial we stated the hypothesis that Cerebrolysin in combination with multimodal monitoring and surgical craniotomy is beneficial for the patients. In retrospective analysis we divided the patients into two groups : with and without cerebrolysin. We also analyzed how cerebrolysin influences the treatment results with the combination with additional neuromonitoring of both invasive intracranial pressure (ICP) measurement and non-invasive saturation in the jugular vein, nirs, ultrasound of the optic nerve diameter. We also analyzed if there is any change in the results of treatment after combining Cerebrolysin with another neuroprotective drug : amantadine. We also analyzed the influence of craniotomy combined with cerebrolysin treatment. In an observational study, we collected information on 56 patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Effects of Neuromonitoring and Cerebrolysin Administration on Outcomes in Patients with Traumatic Brain Injury-An Interventional Pilot Study.
Jarosz K, Kojder K, Skonieczna-Żydecka K, Andrzejewska A, et al · · 2024 · cited 2× · PMID 38256487 · DOI 10.3390/jcm13020353
Verify or expand the search:
- PubMed search for NCT05807503
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cerebrolysin
Trials testing the same drug.
- NCT06339411 — Exploring Cerebrolysin in Late Thrombectomy for Stroke: Blood-brain Barrier Biomarkers and Imaging Insights · EARLY_PHASE1 · not yet recruiting
- NCT06677502 — Cerebrolysin in Critically Ill Patients With Delirium · NA · enrolling by invitation
- NCT05755997 — CERebrolysin In CADASIL · Phase 2 · active not recruiting
- NCT06070753 — A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Str · NA · unknown
- NCT06052787 — Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU · Phase 3 · completed
Other recruiting trials for TBI (Traumatic Brain Injury)
Currently open trials in the same condition.
- NCT07103200 — Evaluation of Decision-Making Fatigue After Traumatic Brain Injury · NA · recruiting
- NCT05205174 — Depth Electrode Detection of Cortical Spreading Depolarization After Traumatic Brain Injury · NA · recruiting
- NCT06867666 — Behavioral Treatment of Insomnia in Active-Duty Service Members With Traumatic Brain Injury · NA · recruiting
- NCT05327829 — Stimulating After Recovery From Traumatic Brain Injury · EARLY_PHASE1 · recruiting
- NCT06467708 — Transcutaneous Auricular Neurostimulation for ICU Patients With Traumatic Brain Injury · NA · recruiting
Other Pomeranian Medical University Szczecin trials
Trials by the same sponsor.
- NCT07370649 — Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study · not yet recruiting
- NCT07328789 — Factors Influencing Cardiac Rehabilitation Success · not yet recruiting
- NCT06809101 — Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Bal · recruiting
- NCT07070609 — Sagittal Spine Balance in Patients With Chest Wall Deformity · active not recruiting
- NCT06743360 — Microanalysis of Changes in 3D Geometry of Orthodontic Mini-implants · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05807503 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pomeranian Medical University Szczecin
- Last refreshed: 11 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05807503.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing